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22 Abstract
23 Objective: Two studies were conducted to develop and validate a questionnaire to 
24 estimate the individual susceptibility to visually induced motion sickness (VIMS). Background: 
25 VIMS is a common side-effect when watching dynamic visual content from various sources, 
26 such as Virtual Reality, movie theatres, or smartphones. A reliable questionnaire tool to predict 
27 the individual susceptibility to VIMS is currently missing. The aim was to fill this gap by 
28 introducing the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). 
29 Methods: Two independent studies were conducted: A survey and an experimental study. 
30 Survey: The VIMSSQ investigated the frequency of nausea, headache, dizziness, fatigue, and 
31 eyestrain when using different visual devices.  Data were collected from a survey of 322 
32 participants for the VIMSSQ and other related phenomena such as migraine. Experimental study: 
33 23 participants were exposed to a rotating visual stimulus that induced VIMS. Participants filled 
34 out the VIMSSQ together with other questionnaires and rated their level of VIMS using the 
35 Simulator Sickness Questionnaire (SSQ). Results:  Survey: The most prominent symptom when 
36 using visual devices was eyestrain, and females reported more VIMS compared to males. 
37 Experimental study: regression analyses suggested that the VIMSSQ is a valuable tool for 
38 predicting VIMS (R2 = .34) as measured by the SSQ, particularly when used in conjunction with 
39 other questions pertaining to the tendency to avoid visual displays and experience syncope (R2 = 
40 .59). Conclusion: We generated normative data for the VIMSSQ and demonstrated its validity. 
41 Application: The VIMSSQ can become a valuable and important tool to predict one’s 
42 susceptibility to VIMS based on self-reports. 
43
44 Keywords: simulator sickness, cybersickness, virtual reality, sex, migraine
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45 Précis
46 The Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ) was developed 
47 and validated across two studies. In conjunction with other measures, the VIMSSQ explained 
48 59% of the variance in VIMS as measured by the SSQ. We conclude that the VIMSSQ is a 
49 valuable tool for estimating individual susceptibility to VIMS.  
50




53 Visually induced motion sickness (VIMS) is a phenomenon similar to traditional motion 
54 sickness and is characterized by a variety of symptoms related to gastric activity (e.g., nausea, 
55 vomiting, stomach awareness), autonomic responses (e.g., pallor, sweating), arousal (e.g., 
56 fatigue, drowsiness, difficulty concentrating), disorientation (e.g., dizziness, vertigo), and/or 
57 oculomotor issues (e.g., eyestrain, blurred vision, headache) (Bos et al., 2008; Golding & Gresty, 
58 2015; Robert S. Kennedy et al., 2010; Keshavarz et al., 2014). In contrast to traditional motion 
59 sickness, actual physical movement is typically missing during VIMS and symptoms are 
60 primarily caused by stimulation of the visual system. The symptomatology of VIMS and 
61 traditional motion sickness are very similar, with oculomotor issues such as eyestrain and blurred 
62 vision being more common in VIMS. Depending on the visual device, various terms have been 
63 used in the literature to describe specific types of VIMS, including video gaming sickness (Frey 
64 et al., 2007), Cinerama sickness, Virtual Reality (VR) sickness (Cobb et al., 1999), cybersickness 
65 (K. M. Stanney & Kennedy, 1997) or simulator sickness (Kennedy et al., 1989). Here, we use 
66 VIMS as a general term that includes all these subcategories. Note that the use of simulators and 
67 VR may involve physical motion in certain cases (e.g., motion-based simulators, head tracking in 
68 VR), and symptoms experienced using these devices may strictly speaking not be purely visually 
69 induced; however, as the visual system is arguably the main contributor to motion sickness-like 
70 sensations in these cases, we will include them under the umbrella of VIMS in the present paper. 
71 The exact prevalence of VIMS remains unclear, but laboratory research suggests that the 
72 percentage of people experiencing VIMS can vary widely from 1% (Klüver et al., 2015) to 80% 
73 under certain circumstances (Cobb, 1999; Stanney, Mourant, et al., 1998; Stanney et al., 1999), 
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74 depending on several factors such as the VR equipment (Frank et al., 1988; Moss & Muth, 
75 2011), the experimental setup (e.g., field-of-view, Bos et al., 2010; Duh et al., 2002), or the 
76 visual content (Bubka et al., 2007; Keshavarz, Philipp-Muller, et al., 2018; Palmisano et al., 
77 2007). Additionally, several factors affect an individual’s susceptibility to VIMS. For instance, 
78 females have been found to report more VIMS than males (Flanagan et al., 2005; Stanney et al., 
79 2020), although the robustness of this finding remains unclear given that some studies could not 
80 identify sex-related differences (Curry et al., 2020; Klosterhalfen et al., 2006). Age has been 
81 discussed as another prominent factor, with older adults often reporting more VIMS compared to 
82 younger adults (Domeyer et al., 2013; Keshavarz, Ramkhalawansingh, et al., 2018). In the 
83 present study, we will consider age and sex-related differences to further enhance our 
84 understanding about the role of these two factors. 
85 The elevated risk for experiencing VIMS is critical for several reasons. VR technologies 
86 have dramatically improved over the last decade, while being affordable and accessible to a 
87 broad population.  Several VR systems (e.g., Oculus Rift, HTC Vive, Playstation VR) offer a 
88 highly realistic, immersive, and multisensory VR experience. In 2018 alone, 3.6 million VR 
89 devices were sold world-wide and these numbers are expected to increase. VR is no longer a 
90 niche product, but is rather a common tool in several domains, including rehabilitation (Massetti 
91 et al., 2018), education (Radianti et al., 2020), research (Loomis et al., 1999), training 
92 (Adamovich et al., 2009), mental health (Rizzo et al., 1998), clinical assessment (Rizzo, 2014), 
93 and personal entertainment (Bates, 1992). The risk of experiencing VIMS can have a dramatic 
94 impact on VR technologies from an economic standpoint and may jeopardize the success and 
95 acceptability of these technologies. However, VIMS poses a health concern not only when using 
96 VR systems, but also for other visual devices such as video games, cinemas, smartphones, and/or 
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97 tablets. Although symptoms associated with VIMS are typically short-lived and resolve within 
98 minutes after stopping, they can occasionally last for several hours and affect the user’s daily 
99 activities (Stanney et al., 1998; Stanney et al., 1999). In addition, VIMS is particularly 
100 problematic for those with compromised health conditions, where symptoms such as nausea, 
101 headache, or dizziness may worsen an underlying medical condition such as migraines and 
102 vestibular disorders. Our modern society increasingly relies on visual technologies and the 
103 problems associated with VIMS will become even more important in the near future. 
104 Over the past decades, several techniques have been introduced to reduce or prevent 
105 VIMS. The list of countermeasures is long and ranges from simple recommendations about the 
106 distance to the visual screen (Bos et al., 2010; Duh et al., 2002), behavioral methods (Keshavarz, 
107 2016; Yen Pik Sang, Billar, et al., 2003), to more complex pharmacological treatments (Golding 
108 & Gresty, 2015). The latter is often associated with unwanted side-effects such as drowsiness 
109 and is therefore not a feasible solution in most situations. Non-pharmacological treatments such 
110 as music (Keshavarz & Hecht, 2014; Peck et al., 2020), controlled breathing (Yen Pik Sang, 
111 Golding, et al., 2003), visual reference about true gravity vertical (Duh et al., 2004; Prothero et 
112 al., 1999), or airflow (D’Amour et al., 2017) can be effective under certain circumstances, but 
113 none of these measures fully prevent VIMS. The most effective treatment available so far 
114 remains habituation (Hill & Howarth, 2000; Smither et al., 2008). That is, repeated exposure to 
115 the same, nauseating stimulus eventually results in reduced VIMS over time, even in severe 
116 cases of VIMS (Rine et al., 1999). However, habituation is time consuming and the specific 
117 tolerance acquired from one type of visual technology may not always generalize to other VIMS-
118 inducing situations. 
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119 Given the lack of reliable methods to prevent VIMS, it is of utmost importance to identify 
120 those who are at risk of experiencing VIMS. Unfortunately, reliable methods to predict the 
121 susceptibility to VIMS do, to the best of our knowledge, not yet exist. Several methods have 
122 been introduced in the past that measure the severity of VIMS after exposure to a VIMS-
123 inducing stimulus, such as the Misery Index((Bos, 2015), the Nausea Profile (Muth et al., 1996), 
124 the Fast Motion Sickness Scale (Keshavarz & Hecht, 2011), or the Simulator Sickness 
125 Questionnaire (SSQ, Kennedy et al., 1993). In contrast, no tool exists that can be assessed prior 
126 to a VIMS inducing stimulus in order to estimate one’s susceptibility to VIMS. Golding 
127 introduced the Motion Sickness Susceptibility Questionnaire (MSSQ; Golding, 1998, 2006) to 
128 predict an individual’s susceptibility to traditional motion sickness. The MSSQ inquires about a 
129 person’s past history of motion sickness as a child or adult. The use of the MSSQ has become 
130 best practice to predict traditional motion sickness, however, the MSSQ was not designed to 
131 predict VIMS. In fact, items referring to visual devices have been deliberately removed from the 
132 MSSQ during the development process because, at the time, visual devices as we know them 
133 today were not as common, and including these items did not add to the overall predictive power 
134 of the MSSQ. Since new visual technologies have greatly increased and can now be considered 
135 mainstream, a tool that focuses on the susceptibility of VIMS is highly desirable. Thus, our 
136 objective is to fill this void by introducing a novel method to predict the susceptibility to VIMS – 
137 the Visually Induced Motion Sickness Susceptibility Questionnaire (VIMSSQ). Importantly, 
138 note that the VIMSSQ was designed as an addition to the MSSQ, and not a necessarily as 
139 substitute thereof.
140 The present paper consists of two main parts. In the first part, we will describe the 
141 development of the VIMSSQ and its relationship to other possible risk factors such as classical 
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142 motion sickness susceptibility, migraine, or dizziness. We will present data from a survey with N 
143 = 322 participants using the VIMSSQ. In the second part, we will present empirical findings 
144 from an experimental study that show the usefulness of the VIMSSQ in predicting VIMS. In this 
145 experimental study, we applied the VIMSSQ prior to exposing participants to a VIMS-inducing 
146 stimulus. VIMS was measured after stimulus exposure using the Simulator Sickness 
147 Questionnaire (SSQ, Kennedy et al., 1993), a widely used questionnaire assessing the severity 
148 and symptomatology of VIMS.
149 Part 1: Development and normative data of the VIMSSQ - Survey study  
150 Methods
151 Development of the VIMSSQ
152 Questionnaire structure. The VIMSSQ was developed with the MSSQ-short (Golding, 
153 2006) in mind. That is, we adopted the assumption that previous incidences of VIMS can 
154 successfully predict future episodes of VIMS. However, as the symptomatology of VIMS is 
155 more diverse compared to traditional motion sickness (e.g., more oculomotor issues and 
156 dizziness; (Lawson, 2014; K. M. Stanney & Kennedy, 1997), we decided to inquire about the 
157 frequency of specific symptoms when using visual devices, rather than asking for an overall 
158 estimation of the level of VIMS for each visual device. Note that this is in contrast to the MSSQ, 
159 which asks how often participants experienced motion sickness without looking at different 
160 symptoms separately. Thus, the VIMSSQ focuses on 5 symptoms: nausea, headache, dizziness, 
161 fatigue, and eyestrain. Nausea and fatigue are cardinal symptoms of both VIMS and traditional 
162 motion sickness, whereas headache, dizziness, and eyestrain are more pronounced in VIMS than 
163 in traditional motion sickness (Golding & Gresty, 2005; Keshavarz et al., 2014; Lawson, 2014). 
164 As previously mentioned, the list of other symptoms for VIMS is long and can include pallor, 
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165 sweating, burping, blurred vision, general discomfort, vertigo etc.. However, in order to reduce 
166 the number of symptoms for inclusion in the VIMSSQ, we decided to focus on symptoms that 
167 (a) are most common in VIMS and (b) the user can easily relate to (e.g., it is difficult to self-
168 observe pallor). 
169 The frequency of each of the 5 symptoms had to be rated for 11 common visual devices. 
170 The visual devices included 2D movie theater, 3D movie theater, IMAX theater, smartphone 
171 (dynamic content like movies), tablet (dynamic content like movies), TV, video games (console 
172 or computer), Head Mounted Displays/VR glasses, stationary platform simulators, moving 
173 platform simulators, large public moving display advertising or information screen. The 
174 frequency of each symptom had to be rated on a 4-point Likert scale (never, rarely, sometimes, 
175 often) for experiences during adulthood (18 years or older), ignoring childhood experiences; 
176 participants could also indicate if they never used a visual device (never used/not applicable: 
177 n/a).  
178 In addition, the VIMSSQ included a part that asked the user about their habits of using 
179 the above mentioned 11 visual devices (How often have you used or experienced any of these 
180 devices or displays during adulthood?). Again, participants could choose between never, rarely, 
181 sometimes, and often. This section allowed the researcher to gain insights into how common the 
182 usage of different visual displays is and it may help to detect differences between populations in 
183 terms of their proficiency with these devices and displays. Finally, a single question at the end of 
184 the VIMSSQ inquired whether participants stopped using any of these devices due to increased 
185 discomfort (Have any of these symptoms stopped you from using any of these devices or made 
186 you actively avoid viewing such displays?). If participants responded with yes, they were asked 
187 to list the types of devices that they stopped using in a free response format. (Note that for the 
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188 final version of the VIMSSQ, we decided to change the response format for the avoidance 
189 question to match the VIMSSQ response format: 0 = never, 1 = rarely, 1 = sometimes, 3 = often). 
190 Overall, the VIMSSQ contained 67 items: 11 items regarding the usage frequency of visual 
191 displays and devices, 55 items regarding the frequency of each of the five symptoms, and 1 
192 question regarding the avoidance of any visual devices and displays.
193  Scoring. The scoring of the VIMSSQ follows Golding’s procedure for calculating the 
194 MSSQ scores (Golding, 2006). That is, responses for each item are assigned a numeric value (0 
195 = never, 1 = rarely, 2 = sometimes, 3 = often, n/a = never used/not applicable). To calculate 
196 scores for each of the five subscales nausea (VIMSSQ-N), headache (VIMSSQ-H), dizziness 
197 (VIMSSQ-D), fatigue (VIMMSQ-F), and eyestrain (VIMSSQ-ES), the following procedure is 
198 applied (see Figure 1): For each subscale, the number of types of visual devices and displays not 
199 used by the participant is identified and counted (i.e., the total number of n/a – not used 
200 responses, maximum = 11). Next, for each subscale, the score for each of the 11 types of 
201 devices/displays is calculated by summing the raw scores for each item (n/a responses counted as 
202 zero). To ultimately calculate each VIMSSQ subscale, we used the formula: 
203 (raw subscale score) * (11) / (11 - n/a total)
204 with ‘raw subscale score = score for either nausea, dizziness, fatigue, headache, or 
205 eyestrain’ and ‘n/a total = the total number of n/a responses’. If no types of visual devices are 
206 experienced, an error due to a division by zero would occur, making it not possible to calculate a 
207 VIMSSQ score and estimate VIMS susceptibility, which also provides an internal consistency 
208 check. The maximum score for each VIMSSQ subscale is 33. A VIMSSQ total score (VIMSSQ-
209 TS) can be calculated by summing the five subscales.
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210 Figure 1 
211 Scoring procedure for the VIMSSQ subscales (upper panel) and the VIMSSQ total score (lower 
212 panel). 
213
214 Note. Refer to the text for a detailed description of the scoring procedure. 
215
216 Participants
217 A total of 332 participants filled out the VIMSSQ either via an online survey using the 
218 platform Qualtrics (n = 140) or as a paper-and-pencil version when they attended experimental 
219 studies at The KITE Research Institute-University Health Network (n = 192). In both cases, 
220 participants gave their written consent first before filling out the VIMSSQ. The online survey 
221 was approved by the research ethics boards of the University Health Network, Canada, and the 
222 University of Westminster, United Kingdom. The respective study protocols for the paper-and-
223 pencil version of the VIMSSQ were all approved by the research ethics board of the University 
224 Health Network, Canada. Ten participants were removed from the data analysis due to 
225 incomplete data sets, resulting in a final sample size of N = 322 (Mage = 32.89 years, SDage = 
226 18.82). The sample consisted of 195 females (Mage = 31.26 years, SDage = 17.53) and 126 males 
227 (Mage = 35.38 years, SDage = 20.45). As differences between females and males have been 
228 suggested with regards to VIMS severity (Flanagan et al., 2005; Stanney et al., 2020) we will 
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229 consider sex as a factor in our analysis. Note that one participant chose not to answer the 
230 question regarding their sex and was therefore excluded from all sex-related statistical analysis. 
231 A detailed description of the age distribution of the sample is given in Figure 2.
232 Figure 2 
233 Participants’ age distribution separated by sex.
234
235 Other baseline measures
236 In addition to the VIMSSQ, participants filled out questionnaires related to concepts 
237 relevant to VIMS, including their susceptibility to traditional motion sickness, migraines, and the 
238 impact of dizziness on daily living. Motion sickness susceptibility was measured using the short 
239 version of the MSSQ (Golding, 2006). The MSSQ inquires about the frequency of motion 
240 sickness (not applicable, never, rarely, sometimes, often) when travelling or using different 
241 modes of transportation (e.g., car, bus, ship, airplane, funfair rides) as a child (before the age of 
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242 12) and as an adult (last 10 years). The tendency to experience migraines has been linked to the 
243 experience of VIMS in the past (Golding & Patel, 2017) and was measured using the Migraine 
244 Screen Questionnaire (Láinez et al., 2010), consisting of five items that are rated on a binary 
245 scale (0 = no, 1 = yes). Questions include whether a person experiences frequent or intense 
246 headaches and whether the headaches last more than four hours. A total score was calculated by 
247 summing the values for each response (max. score = 5), with a score of 4 or higher indicates high 
248 propensity to experience migraines. The SWID4, a set of four social, travel, family and work-
249 related questions which has been validated previously (Bronstein et al., 2010) was used to assess 
250 the impact of dizziness on social life and work. Participants had to provide yes or no responses to 
251 these questions, and the values (no = 0, yes = 1) were summed together to create a total score for 
252 SWID (max. score = 4). A single binary item concerning the susceptibility to vasovagal syncope 




257 An overview of the usage of visual devices is provided in Figure 3 for male and female 
258 participants. To account for the nonnormality of the data (ordinal scales), non-parametric 
259 Wilcoxon Rank-Sum tests were calculated to detect differences in the frequency of visual device 
260 usage for males and females. Results showed that male participants played significantly more 
261 video games than female participants (W = 8080.50, p < .001). No other sex-related differences 
262 were found for any of the other visual devices.
263 Figure 3
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264 Relative frequency of device usage (in percent) for females (top panel), males (center panel), and 
265 for both combined (bottom panel)
266
267 Symptom frequency, VIMSSSQ scores, device avoidance, and sex
268 The frequency of each VIMS-related symptom for each of the visual devices is shown in 
269 Figure 4. The mean scores for the VIMSSQ subscales nausea, dizziness, fatigue, headache, and 
270 eyestrain as well as the VIMSSQ total score are shown in Figure 5 for female and male 
271 participants. Detailed statistical information including percentiles for each VIMSSQ subscale are 
272 given in Table 1. Independent samples t tests (degrees of freedom corrected for unequal 
273 variances, Holm-corrected alpha level, Cohen’s d as effect size) were calculated to investigate 
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274 sex-related differences with regards to the VIMSSQ subscales. Females reported significantly 
275 higher scores for the VIMSSQ subscales dizziness, t(278) = 2.625, p = .025, headache, t(309) = 
276 4.327, p < .001, d = .47, d = .30, fatigue, t(296) = 2.476, p = .025, d = .27, eyestrain, t(291) 
277 =3.120, p = 002, d = .35, and the total score, t(291) = 3.577, p < .001, d = .40,. No significant 
278 difference showed for the VIMSSQ subscale nausea, t(257) = 1.660, p = .086, d = .19.
279 Overall, 29.5% of all users indicated that the presence of VIMS-related symptoms caused 
280 them to stop (or significantly reduce) the use of certain visual devices. The most common 
281 devices that users try to avoid include 3D movies (14.3%), smartphones (5.3%), IMAX theatres 
282 (4.3%), video games (3.4%), simulators (4.0%), and VR (2.8%).
283
284
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285 Figure 4 
286 Relative frequency of reported symptoms for each of the visual devices averaged across sex 
287
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288 Note. Participants who never have used a particular visual device were removed to enhance 
289 comparability across devices, resulting in different sample sizes for TV (n = 309), smartphone (n 
290 = 293), tablet (n = 272), 2D movies (n = 310), 3D movies (n = 288), IMAX theatre (n = 256), 
291 videogames (n = 252), simulator moving (n = 189), simulator stationary (n = 298), VR (n = 119), 
292 and commercial displays (n = 262). 
293 Figure 5
294 Mean scores for the VIMSSQ subscales nausea, headache, dizziness, fatigue, and eyestrain 
295 averaged across visual devices and separated by sex.
296
297 Note. Error bars represent SD. Single dots represent individual scores for each participant. 
298 *p < .05, **p < .01, ***p < .01. 
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299 Table 1
300 Descriptive statistics for the VIMSSQ subscales separated by sex
FEMALE (n = 195)
VIMSSQ M SD Range P10 P25 Med P75 P90
Nausea 4.39 4.96 0 – 20.9 0.00 0.00 3.00 6.29 11.50
Headache 6.62 6.91 0 – 26.4 0.00 0.00 4.71 11.00 17.95
Dizziness 4.29 4.99 0 – 23.22 0.00 0.00 2.75 6.94 12.31
Fatigue 6.35 7.39 0 – 33.00 0.00 0.00 3.67 11.00 16.30
Eyestrain 10.94 8.34 0 – 33 0.00 3.90 9.62 16.75 22.66
Total score 32.59 26.52 0 – 105.6 2.75 11.00 26.40 49.19 71.50
MALE (n = 126)
VIMSSQ M SD Range P10 P25 Med P75 P90
Nausea 3.42 5.22 0 – 24.44 0.00 0.00 0.00 5.30 11.50
Headache 3.65 5.33 0 – 28.11 0.00 0.00 1.47 4.93 10.31
Dizziness 2.84 4.71 0 – 30.56 0.00 0.00 1.05 4.09 7.62
Fatigue 4.44 6.29 0 – 33 0.00 0.00 1.22 6.81 12.70
Eyestrain 8.19 7.30 0 – 33 0.00 2.44 6.94 12.43 16.50
Total score 22.54 23.23 0 – 146.67 0.00 6.70 16.50 30.25 51.56
TOTAL (N = 322)
VIMSSQ M SD Range P10 P25 Med P75 P90
Nausea 4.00 5.07 0 – 24.44 0.00 0.00 2.10 6.29 11.90
Headache 5.44 6.49 0 – 28.11 0.00 0.00 2.75 8.25 15.12
Dizziness 3.71 4.92 0 – 30.56 0.00 0.00 2.00 5.50 11.00
Fatigue 5.62 7.02 0 – 33.00 0.00 0.00 2.88 9.90 15.68
Eyestrain 9.87 8.80 0 – 33.00 0.00 3.00 8.80 14.58 20.61
Total score 28.62 25.68 0 – 146.67 1.83 9.17 22.00 41.95 66.00
301 Note. Med = Median, P10 = 10th Percentile, P25 = 25th Percentile, P75 = 75th Percentile, P90 = 
302 90th Percentile
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303 Scale reliability and factor analysis
304 An exploratory factor analysis was conducted on the VIMSSQ subscales nausea, 
305 dizziness, fatigue, headache, and eyestrain (frequency of use and avoidance items were omitted) 
306 to examine the factor structure of the VIMSSQ. Bivariate distributions between each variable did 
307 not suggest the presence of nonlinearity. To account for ordinal nature of the items comprising 
308 each subscale, Spearman rank-ordered correlations (N = 322) were utilized for the factor analysis 
309 and were all significant (Table 2). 
310 Table 2
311 Spearman correlations between VIMSSQ subscale measures
VIMSSQ subscale
Nausea Headache Dizziness Fatigue Eyestrain
Nausea 1.00
Headache .59 1.00
Dizziness .58 .53 1.00
Fatigue .34 .56 .42 1.00
Eyestrain .44 .69 .45 .63 1.00
312 Note. All correlations are significant at p < .001.
313 Due to violations of the multivariate normality assumption as assessed by Mardia’s Test 
314 (skewness coefficient = 622.76, p<.001; kurtosis coefficient = 29.57, p<.001), a Weighted Least 
315 Squares (WLS) estimation method was chosen (Flora & Curran, 2004). All factor models were 
316 estimated using the lavaan Package (Rosseel, 2012) on the statistical software R (version 4.0.2; 
317 R Core Team, 2020). Results suggested a one-factor solution for the set of 5 VIMSSQ subscales 
318 (Eigenvalue: 3.27), with a reasonable model fit for the latent factor accounting for 57% of the 
319 variance (root-mean-square residuals = .07). All variables had factor loadings of at least .68 and 
320 communality values within the range of .46 (VIMSSQ-N) and .77 (VIMSSQ-H). Specifically, it 
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321 was found that for every 1-SD increase in the latent factor, VIMSSQ-N, VIMSSQ-H, VIMSSQ-
322 D, VIMSSQ-F, and VIMSSQ-ES subscales are predicted to increase by .68, .88, .71, .73 and .77, 
323 respectively. A moderate to high MacDonald’s omega of .87 demonstrated good scale reliability 
324 of the VIMSSQ.
325 VIMSSQ and other variables 
326 Mean scores for participants’ susceptibility to traditional motion sickness, migraines, and 
327 dizziness are shown in Table 4. Independent samples t tests showed that females reported higher 
328 scores than males with respect to the MSSQ-adult subscale, t(288) = 5.051, p < .001, d = .57, and 
329 the MSSQ-child subscale, t(279) = 2.32, p = .021, d = .27. Non-parametric tests (Wilcoxon) 
330 showed that females also reported significantly higher scores than males with regards to 
331 migraines, W = 14931.0, p < .001, dizziness, W = 13271.0, p = .032, and syncope, W = 14557.0, 
332 p < .001. Correlations were calculated for each of the VIMSSQ subscales, the MSSQ-child and 
333 MSSQ-adult, migraine, dizziness, and age. Results are given in Table 5 and indicate that VIMS 
334 and MS are significantly correlated with each other. Interestingly, we found significant, negative 
335 correlations between age and all VIMSSQ subscales, indicating that VIMS is less severe with 
336 increasing age. 
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337 Table 4













Female 8.34 (6.76) 6.83 (6.01) 1.68 (1.73) 0.26 (0.69) 0.28 (0.46)
Male 6.62 (5.85) 3.68 (4.67) 1.00 (1.41) 0.16 (0.67) 0.09 (0.28)
p valueb < .001 .021 < .001  .033 < .001
339 Note. a MSSQ data for 29 participants were incomplete and could not be calculated; 




344 Correlations between VIMSSQ, MSSQ, migraine, dizziness, and age
VIMSSQ subscale
Measure Nausea Headache Dizziness Fatigue Eyestrain Total score
MSSQ childa .38** .28** .31** .19** .28** .35**
MSSQ adulta .47** .39** .29** .27** .37** .44**
Migraineb .16* .36** .14 .19** .29** .30**
SWID4b .16* .14 .22** .05 .14 .16*
Syncopeb .11 .26** .24** .18* .22** .25**
Agec -.24** -.36** -.17** -.26** -.40** -.37**
345 Note. a Pearson correlations (n = 293), b Spearman correlations (n = 322), c Age information for 
346 three participants were missing; Pearson correlations (n = 319). *p < .05, **p < .01
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347 Discussion: Survey study
348 The results of the online survey delivered insights into the frequency and severity of 
349 different VIMS-related symptoms associated with each device. We found that eyestrain is the 
350 most common symptom reported by users, whereas nausea and dizziness are experienced less 
351 frequently across all visual devices. Oculomotor issues such as eyestrain have been known to be 
352 one of the primary symptoms of VIMS, and this family of symptoms is typically more prominent 
353 than gastrointestinal disturbances in VIMS compared to traditional motion sickness (Keshavarz 
354 et al., 2014; K. M. Stanney & Kennedy, 1997). Thus, it seems plausible that eyestrain was the 
355 most common symptom when using visual devices. 
356 We also found that females reported significantly higher VIMS scores compared to males 
357 across all symptoms but nausea. Sex-related differences in VIMS (Flanagan et al., 2005; 
358 Klosterhalfen et al., 2006) and traditional motion sickness (Dobie et al., 2001; K. M. Stanney et 
359 al., 2003) have been documented in previous studies. The reason for these differences are not 
360 well known; hormonal aspects have been discussed as a potential cause, as the menstruation 
361 cycle has been shown to affect women’s susceptibility to motion sickness (Golding et al., 2005; 
362 Grunfeld & Gresty, 1998; Hemmerich et al., 2019). It has also been speculated that females may 
363 be more open and more willing to report VIMS compared to men (Ladwig et al., 2000), but 
364 scientific evidence supporting this claim is weak (Dobie et al., 2001). Note, however, that 
365 Cohen’s effect sizes indicate that the sex-related differences found for the VIMSSQ subscales 
366 are rather weak or moderate at best. Furthermore, we found negative correlations between age 
367 and the VIMSSQ subscales, suggesting that users report less VIMS with increasing age. This 
368 finding is surprising, as laboratory research showed that older adults typically report more VIMS 
369 compared to younger adults (Brooks et al., 2010; Keshavarz, Ramkhalawansingh, et al., 2018). 
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370 However, our findings could be due to the fact that older adults tend to use fewer visual displays 
371 than younger adults and use them less frequently, which could explain the overall lower VIMS 
372 scores. It could also be possible that older adults report less VIMS due to habituation as a result 
373 of continuous exposure to visual devices. More thorough and systematic studies are needed to 
374 better understand the relationship between VIMS and age.  
375 Moderately strong correlations between the VIMSSQ scores and other related concepts 
376 such as the susceptibility to traditional motion sickness, dizziness, and migraine were found. 
377 These correlations suggest that the susceptibility to VIMS is indeed linked to the susceptibility to 
378 traditional motion sickness, but that these two phenomena are also independent from each other 
379 to some extent, highlighting the need to develop a tool that can specifically predict an 
380 individual’s susceptibility to VIMS. 
381 With regards to the general usage of visual devices, we found that TV, 2D movies, and 
382 smartphones are the most frequently used visual devices for dynamic visual content. In contrast, 
383 VR glasses were not commonly used and more than 60% of all participants have never used VR 
384 glasses before. This finding is somewhat surprising, given that VR devices are becoming more 
385 popular in various domains, such as entertainment, research, or teaching, and have become more 
386 affordable and accessible to a broader population. However, our findings suggest that VR is yet 
387 to become mainstream and is still a novelty to the majority of survey participants. Around 30% 
388 of participants indicated that VIMS-related symptoms make them reduce or fully avoid the use of 
389 certain visual devices, particularly 3D movies. This demonstrates that VIMS is indeed a severe 
390 issue that interrupts almost a third of users and requires them to adjust their behaviour. 
391 Interestingly, the only sex-related difference with regards to the usage of devices showed for 
392 videogames, with males playing significantly more videogames than females, supporting 
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393 previous studies that showed similar sex differences for video game usage (Ogletree & Drake, 
394 2007; Terlecki et al., 2011). No other differences between males and females showed with 
395 respect to the usage of visual displays.
396 The scale reliability of the VIMSSQ was high as indicated by MacDonald’s Omega and 
397 was similar to previous findings (Golding & Keshavarz, 2017). A one-factorial solution for the 
398 VIMSSQ was found to be the best fit, suggesting that all subscales of the VIMSSQ indeed 
399 measure the latent construct of VIMS susceptibility. Of note, headache and eyestrain had a 
400 stronger influence on overall VIMS susceptibility compared to dizziness, fatigue, and nausea. As 
401 a next step, we empirically tested the efficacy of the VIMSSQ questionnaire to predict VIMS 
402 provoked in an experimental study. The next section will describe the validation process for the 
403 VIMSSQ. 
404 Part 2: Validating the VIMSSQ –  Experimental study
405 Methods
406 Participants
407 Twenty-three healthy younger adults (15 females, Mage = 25.26 years, SD = 3.89) 
408 participated in an experimental study at The KITE Research Institute, the research arm of the 
409 Toronto Rehabilitation Institute at the University Health Network (UHN). The study complied 
410 with the tenets of the Declaration of Helsinki and was approved by the Institutional Review 
411 Board at UHN.  Participants were naïve with respect to the purpose of the study. Written consent 
412 was obtained prior to the beginning of the study and participants were reimbursed for their time 
413 commitment. 
414 Study design, stimuli, and experimental procedure Commented [KB1]:  Brandy: I added more details 
about the study, please check carefully and edit if 
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415 The objective of this study was to investigate the influence of multisensory cues on the 
416 perception of illusory self-motion, or vection. As vection and VIMS are known to often co-occur 
417 (see Keshavarz et al., 2015, for an overview), we saw this study as an appropriate choice to 
418 validate the VIMSSQ. Participants were seated in a rotatable chair in the center of a dome-
419 shaped laboratory (KITE’s StreetLab) with five projectors creating a large, curved image with a 
420 field-of-view of 240° horizontally and 110° vertically surrounding them. Participants were 
421 exposed to a revolving stimulus that induced the sensation of self-motion along the yaw axis 
422 (circular vection). The stimulus contained visual, auditory, and/or tactile cues (see Figure 6): the 
423 visual cues consisted of a photorealistic virtual office scene,  the auditory cues contained three 
424 stationary sound sources (continuous sound of a fan, telephone, and printer) placed within the 
425 same virtual office scene, and the tactile cues were provided via a circular handrail within reach 
426 that rotated around the participants. All participants were exposed to trials that either included a 
427 single sensory input (visual-only, auditory-only, tactile-only), a combination of two (audio-
428 visual, audio-tactile, visual-tactile), and a combination of all three sensory cues (audio-visual-
429 tactile). Additionally, the visible field-of-view (FOV) was systematically manipulated by 
430 occluding the periphery of the projection screen to 0° (no visual cues), 45°(small FOV), 120° 
431 (medium FOV), and 240° (large FOV). Thus, a 2 x 2 x 4 factorial design including the within-
432 subjects factors visual cues (no visual cues, small FOV, medium FOV, large FOV), auditory cues 
433 (present, absent), and tactile cues (present, absent) was chosen, resulting in 16 trials with 
434 different sensory cue combinations. Each trial was 45s long (2.5s acceleration phase, 40s 
435 constant circular motion, 2.5s deceleration) and was repeated four times, resulting in a total of 64 
436 trials with a combined duration of approximately 45 minutes. Participants were asked to focus on 
437 a fixation point superimposed at the center of the screen. Between trials, the screen was 
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438 blackened and participants were asked to verbally rate vection intensity and duration. Trials were 
439 separated into 4 different blocks (16 trials each, randomized order) with a short rest break 
440 between the blocks. The vection results and their relationship to multisensory cues are presented 
441 and discussed elsewhere (Murovec et al., 2020). 
442 Figure 6











Prior to the experiment, 
445 participants filled out the same questionnaires used for the online survey, including the 
446 VIMSSQ, the avoidance question, the MSSQ-short, the Migraine Screen Questionnaire, the 
447 SWID4, and the single binary item concerning the susceptibility to vasovagal syncope. Note that 
448 the response format for the avoidance question was modified to match the VIMSSQ response 
449 format (0 = never, 1 = rarely, 1 = sometimes, 3 = often). Following the experiment (i.e., after the 
450 last trial), VIMS symptomology was measured using the Simulator Sickness Questionnaire 
451 (SSQ; Kennedy et al., 1993). The SSQ contains 16 items associated with VIMS, such as nausea, 
452 dizziness, fatigue, or blurred vision, that have to be rated on a scale from 0 (not at all) to 3 
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453 (severe). Three subscales (nausea, disorientation, oculomotor) as well as a total score can be 
454 generated using specific factor weightings suggested by Kennedy et al. (1993). 
455 Results
456 All participants reported elevated levels of VIMS after the experiment as measured by the 
457 SSQ subscales nausea (M = 22.81, SD = 19.02), oculomotor (M = 28.34, SD = 19.01), 
458 disorientation (M = 36.92, SD = 39.95), and the total score (M = 32.85, SD = 24.37). The results 
459 for the VIMSSQ subscales and the total score, the MSSQ-short, the Migraine Screen 
460 Questionnaire, and the SWID4 are given in Table 6. With regards to avoidance, 39.1% of the 
461 participants reported that they occasionally avoid visual devices due to VIMS (17.4% rarely, 
462 21.7% sometimes), whereas the majority of the participants do not avoid using visual devices 
463 (60.9%). Four of the 23 participants (17.4%) experienced syncope in the past. 
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464 Table 6
465 Mean and SD for all questionnaire data
Female (n = 15) Male (n = 8)
Measure M SD M SD
VIMSSQ Nausea 4.98 6.25 1.30 1.60
VIMSSQ Headache 6.25 5.34 2.09 1.90
VIMSSQ Dizziness 3.95 4.09 0.78 0.93
VIMSSQ Fatigue 5.68 5.95 1.99 3.70
VIMSSQ Eyestrain 8.37 6.20 5.21 4.35
VIMSSQ total score 29.23 19.05 11.36 7.76
Migraine 1.60 2.00 1.13 2.00
SWID 0.27 1.00 0.00 0.00
MSSQ-child 9.69 7.61 4.66 3.30
MSSQ-adult 7.98 5.33 2.50 2.13
466 Linear regression models were calculated to estimate the amount of VIMS variance 
467 (measured by the SSQ total score) explained by different predictive variables. That is, the 
468 VIMSSQ total score, the MSSQ-short subscales child and adult, the Migraine Screen 
469 Questionnaire total score, the SWID4 total score, the avoidance tendency score, and the syncope 
470 score were included in the regression model. A stepwise forward approach was chosen. 
471 Correlations between the SSQ and the predictive factors are shown in Table 7. 
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472 Table 7











SSQ .60** .69** .38* .49** .46* .11 .36*
474 Note: * p < .05, ** p < .01
475 Prior to the stepwise procedure, an initial baseline regression model was constructed to 
476 examine the raw relationship between the VIMSSQ total score and the SSQ total score (Figure 
477 5). This model was found to be significant, F(1, 21) = 11.52, p = .003, accounting for 35.4% 
478 (multiple R2) of the variance in VIMS symptomology. Specifically, it was found that the SSQ 
479 total score is predicted to increase by .595 SD units for every 1 SD increase in the VIMSSQ total 
480 score. The model that explained the largest amount of variance contained the VIMSSQ total 
481 score, avoidance, and syncope as predictors, accounting for 59% (adjusted R2) of the total 
482 variance in the SSQ total score. This model was shown to be a significant improvement from the 
483 baseline model, F(2, 19) = 7.85, p = .003. The standardized regression coefficients indicated that 
484 avoidance had the strongest influence on the SSQ total score, followed by the VIMSSQ total 
485 score and syncope, where every 1 SD increase in these variables predicted an increase in the SSQ 
486 total score of .506, .381, and .196, respectively. No other variables significantly increased the 
487 explained variance further.
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488 Figure 5
489 Scatterplot displaying the relationship between the SSQ total score and the VIMSSQ total score 
490 (multiple R2 = 0.354)
491
492 Discussion: Experimental study 
493 The results of the experimental study demonstrated that the VIMSSQ is a valuable tool to 
494 predict the occurrence of VIMS, particularly when combined with other questionnaires; the 
495 VIMSSQ alone explained 34% of VIMS variance as measured by the SSQ total score, and this 
496 score increased to 59% when questions about avoidance tendencies and syncope experiences 
497 were added. In contrast, adding the MSSQ (child and adult) or questions about migraines and 
498 dizziness did not increase the amount of explained variance. 
499 These results are in support of previous findings, suggesting that the VIMSSQ can be 
500 useful in predicting the occurrence of VIMS (Golding & Keshavarz, 2017; Keshavarz et al., 
501 2019). For instance, a study by Keshavarz et al. (2019) measured the level of VIMS in older and 
502 younger adults who participated in a simulated driving study. The VIMSSQ was administered 
503 before the drive and was compared to the level of reported VIMS as measured via the Fast 
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504 Motion Sickness Scale (FMS, Keshavarz & Hecht, 2011). Results showed that the VIMSSQ 
505 worked equally well for younger and older adults and that the VIMMSQ subscale nausea alone 
506 was able to predict approximately a third of the variance in the FMS data. When other variables 
507 were added, the predictive power increased to more than 40% of the variance. 
508 General Discussion and Conclusion
509 The aim of the resent paper was to introduce the VIMSSQ as a questionnaire that can 
510 estimate an individual’s susceptibility to VIMS. Thus, the present paper described the 
511 development process of the VIMSSQ, gathered data from a large sample in order to establish 
512 first normative data that could be used as a benchmark, and demonstrated in an experimental 
513 study that the VIMSSQ can be a useful tool predicting the occurrence of VIMS as measured by 
514 the SSQ. Together with our previous work on the VIMSSQ (Golding & Keshavarz, 2017; 
515 Keshavarz et al., 2019), we are gaining confidence in recommending the use of the VIMSSQ in 
516 combination with other scales and questions to detect those users of visual devices who might be 
517 at elevated risk of experiencing VIMS. Notably, the VIMSSQ seems superior to other existing 
518 questionnaires (e.g., MSSQ) in predicting the occurrence of VIMS. 
519 Despite the promising results, additional investigations, particularly with larger 
520 participant samples across various populations and various experimental settings (e.g., different 
521 visual displays, different stimuli), are highly desirable to further determine the predictive power 
522 of the VIMSSQ. For instance, the scatterplot shown in Figure 5 depicts an “outlier” with a very 
523 high VIMSSQ score (above 90th percentile of the norm). Removing this participant from the 
524 regression model substantially increased the explained variance of the SSQ to 75%. Thus, studies 
525 with larger samples sizes are recommended to establish a more robust model of the VIMSSQ’s 
526 predictive power. In addition, future studies should also compare the VIMSSQ to different VIMS 
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527 measures that are more tailored to certain visual devices. Although the SSQ is the most 
528 commonly used questionnaire for assessing VIMS, it was originally designed for the use of 
529 driving and flight simulators. More recent studies questioned the appropriateness of the SSQ for 
530 instance in the context of VR, suggesting that modified versions of the SSQ might be more 
531 useful (Sevinc & Berkman, 2020). Thus, we recommend to further investigate the predictive 
532 power of the VIMSSQ for alternative measures of VIMS. 
533 One of the main disadvantages of the VIMSSQ is that it is quite lengthy and can be 
534 somewhat overwhelming for participants. Thus, a short version of the VIMSSQ was recently 
535 proposed and tested (Golding et al., submitted). The short version of the VIMSSQ has a similar 
536 structure to the VIMSSQ (i.e., same five symptoms), but does not differentiate between the 
537 different visual devices. Instead, users are asked to rate the occurrence of nausea, headache, 
538 dizziness, fatigue, and eyestrain for all visual displays together (ranging from 0 = never to 3 = 
539 often), resulting in a total of 5 symptom items. The avoidance question from the VIMSSQ was 
540 retained, making the short version of the VIMSSQ a 6-item long questionnaire. In the 
541 experimental study by Golding et al. (submitted), 30 participants were exposed to a nauseating 
542 visual stimulus and filled out the short version of the VIMSSQ together with the same set of 
543 questionnaires described in the present study (e.g., migraine, SWID4, syncope, MSSQ). Similar 
544 to the present findings, the VIMSSQ-short explained approximately 34% of the total variance of 
545 VIMS as measured by the VIMSSQ, and this number increased to 56% when other 
546 questionnaires were added. This is first proof that a short version of the VIMSSQ might be 
547 similarly effective to the long version of the VIMSSQ. However, a direct comparison between 
548 the VIMSSQ long and short version is needed in the future and should be conducted with a 
549 larger sample size. 
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550 Key points
551 - Visually induced motion sickness (VIMS) is a common issue when using visual devices
552 - Most common symptoms include eyestrain, fatigue, headache, dizziness, and nausea
553 - Two studies were conducted to develop and validate the Visually Induced Motion 
554 Sickness Susceptibility Questionnaire (VIMSSQ) 
555 - The VIMSSQ can be a valuable tool to estimate individual susceptibility to VIMS
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